Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 6/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.44 |
| ▸ | PDE4A | P27815 | 12/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559411 | 0.92 | PDE4A (0.53) | TNFPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2979242 | 0.85 | TNF (0.49) | TNFPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3557145 | 0.85 | PDE4A (0.45) | TNFPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3558301 | 0.84 | PDE4A (0.44) | TNFPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3563179 | 0.82 | PDE4A (0.51) | TNFPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3557599 | 0.82 | PDE4B (0.42) | TNFPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3395541 | 0.82 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4025658 | 0.79 | TNF (0.41) | TNFPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4031151 | 0.78 | TNF (0.40) | TNFPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1143842 | 0.78 | TNF (0.40) | TNFPDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587474-B1 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2009-11-18 | — | — | EP | claimed |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | TRIMERIS, INC. | 2007-03-29 | — | — | US | claimed |
| US-7173058-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2007-02-06 | — | — | US | claimed |
| EP-1587474-A4 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1587474-A2 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-10-26 | — | — | EP | claimed |
| EP-1587474-A3 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-09-15 | — | — | EP | claimed |
| US-20040204448-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-10-14 | — | — | US | claimed |
| WO-2004060313-A2 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-07-22 | — | — | WO | claimed |
| US-8263637-B2 | Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2258363-A1 | Compositions for treatment of cancers | CELGENE CORPORATION (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7842691-B2 | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2010-11-30 | — | — | US | disclosed |
| US-7776907-B2 | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide | CELGENE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1587474-B1 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2004037207-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2004034962-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003097040-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003086373-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087333-A2 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | IL2, HDGF, VEGFA | TNF 7/4885PDE4B 1724/4885PDE4A 1843/4885 |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | IL6, IL2, IL6ST | TNF 6/4885PDE4B 561/4885PDE4A 498/4885 |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE4B, PDE4D | TNF 4126/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20040204448-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE4B, PDE4D | TNF 4126/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.